Centanafadine PDUFA July 24, 2026: Pipeline and Access for Otsuka's NDSRI

The attention of CNS market-access and pipeline-planning teams is focused on the upcoming regulatory decision for centanafadine, Otsuka Pharmaceutical's investigational non-stimulant candidate for Attention-Deficit/Hyperactivity Disorder (ADHD). As the Food and Drug Administration (FDA) approaches the July 24, 2026 Prescription Drug User Fee Act (PDUFA) target action date, clinical-development and formulary decision-makers are evaluating how this first-in-class agent will fit into a crowded, supply-constrained therapeutic landscape. With the FDA reviewing the New Drug Application (NDA) under priority review, the potential approval of a once-daily extended-release capsule with a low abuse-potential profile could offer a new alternative for the millions of pediatric, adolescent, and adult patients navigating the persistent stimulant shortage.

Quick answer

What is the scenario question? Our CNS market-access and pipeline teams need to plan for a potential July 24, 2026 approval of Otsuka's centanafadine. What is it, what did the trials show, and how should we position it?

Direct Answer: Centanafadine is Otsuka's investigational, once-daily extended-release capsule and the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD in children, adolescents, and adults. The FDA accepted the NDA on January 27, 2026 with priority review and set a PDUFA target action date of July 24, 2026. The filing is supported by four pivotal Phase 3 trials showing statistically significant improvements versus placebo on the ADHD Rating Scale-5 in pediatric and adolescent patients and on the ADHD Investigator Symptom Rating Scale in adults, with a tolerability profile (decreased appetite, nausea, rash, fatigue, abdominal pain, somnolence in younger patients; decreased appetite and headache in adults) and a reportedly low abuse potential that, if confirmed at approval, positions it as a non-stimulant option distinct from atomoxetine and viloxazine at a time of persistent stimulant shortage. CDC estimates about 7 million US children and 15.5 million adults have ADHD.

---

What is centanafadine and why is its mechanism called an NDSRI?

Centanafadine (formerly EB-1020) represents a pharmacological departure from both traditional stimulants and currently marketed non-stimulants. It is classified as a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), often referred to as a triple reuptake inhibitor (TRI).

To understand its differentiation, it is useful to contrast its receptor affinity with existing ADHD therapies. Traditional stimulants—namely methylphenidate- and amphetamine-based formulations—work primarily by increasing synaptic concentrations of dopamine and norepinephrine. Methylphenidate acts as a reuptake inhibitor of these two neurotransmitters, while amphetamines act as both reuptake inhibitors and releasing agents via the trace amine-associated receptor 1 (TAAR1). The elevation of synaptic dopamine in the mesolimbic pathway is the primary driver of both the high efficacy of stimulants and their susceptibility to abuse, leading to their classification as Schedule II controlled substances.

Conversely, approved non-stimulant medications for ADHD, such as atomoxetine (Strattera) and viloxazine (Qelbree), are selective norepinephrine reuptake inhibitors (NRIs). While they increase norepinephrine and, to a lesser extent, dopamine in the prefrontal cortex, they lack meaningful affinity for dopamine transporters in the subcortical reward centers. Consequently, they do not carry abuse potential and are not scheduled substances, but their clinical effect sizes have historically lagged behind those of stimulants.

Centanafadine blocks the reuptake of all three monoamine neurotransmitters. In vitro binding studies demonstrate that it inhibits the reuptake of norepinephrine, dopamine, and serotonin with a specific ratio of potency:

• Norepinephrine transporter (NET): Highest potency inhibition
• Dopamine transporter (DAT): Moderate potency inhibition
• Serotonin transporter (SERT): Lower but physiologically relevant potency inhibition

By combining potent norepinephrine reuptake inhibition with moderate dopamine reuptake inhibition, centanafadine aims to deliver a stronger clinical efficacy signal than selective NRIs without achieving the rapid, high-occupancy dopamine spikes that trigger the abuse-reward pathway. The inclusion of serotonin transporter inhibition is hypothesized to contribute to emotional regulation and executive-functioning improvements, which are frequently impaired in patients with ADHD. If approved, centanafadine would be the first NDSRI available in the US for ADHD.

---

What is the FDA review timeline and the July 24, 2026 PDUFA date?

The regulatory pathway for centanafadine has progressed rapidly in 2026. Otsuka announced on January 27, 2026 that the FDA had accepted its New Drug Application (NDA) for priority review. A priority review designation is granted to applications for drugs that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. This designation compresses the FDA’s standard ten-month review clock to a target of six months from the filing acceptance date.

The FDA established the PDUFA target action date of July 24, 2026. This timeline is a critical milestone for Otsuka, which has spent years developing the molecule through its subsidiary, Astex Pharmaceuticals, and in collaboration with other development partners.

The scope of the NDA submission is highly comprehensive, seeking simultaneous approval for three distinct patient populations:

1. Children (ages 6 to 12)
2. Adolescents (ages 13 to 17)
3. Adults (ages 18 to 55)

Securing priority review for both adult and pediatric indications at the outset is relatively rare in ADHD drug development, where pediatric data are often delayed or filed as subsequent supplements. The concurrent submission was made possible by the parallel execution of Otsuka’s Phase 3 clinical trial programs across the pediatric and adult age spectrum, allowing for a single unified review of the molecule's risk-benefit profile.

CNS pipeline analysts note that upcoming FDA PDUFA decisions represent a critical sector watch list. Centanafadine's review will be heavily scrutinized for any signal of advisory committee meetings, requests for risk evaluation and mitigation strategies (REMS), or scheduling determinations by the Drug Enforcement Administration (DEA).

---

What did the four Phase 3 trials show in children, adolescents, and adults?

The NDA submission is anchored by a robust clinical database comprising four pivotal Phase 3 randomized, double-blind, placebo-controlled trials. These trials evaluated the efficacy, safety, and tolerability of centanafadine extended-release formulations across more than 1,800 patients (two adult trials of 446 and 430 participants, an adolescent trial of 459, and a pediatric trial of 480).

Adult Phase 3 Efficacy Data

The adult clinical program consisted of two identical, parallel-group, multi-center trials evaluating adults aged 18 to 55 with a confirmed diagnosis of ADHD. In these studies, patients were randomized to receive centanafadine sustained-release (SR) at doses of 200 mg daily, 400 mg daily, or placebo over a six-week treatment period. Efficacy was measured using the ADHD Investigator Symptom Rating Scale (AISRS), a validated investigator-rated scale assessing the 18 DSM-5 symptom criteria.

The primary publications (such as Adler et al., Journal of Clinical Psychopharmacology 2022) and subsequent pooled analyses demonstrated that centanafadine met its primary endpoints with statistical significance:

• Trial 1 Results: In the first adult trial, patients receiving 200 mg/day of centanafadine achieved a least-squares (LS) mean difference of minus 3.16 versus placebo on the AISRS score at day 42. Those receiving 400 mg/day achieved an LS mean difference of minus 2.74 versus placebo. Both comparisons were statistically significant.
• Trial 2 Results: In the second adult trial, the LS mean differences versus placebo were even more pronounced. The 200 mg/day arm achieved an LS mean difference of minus 4.01, and the 400 mg/day arm achieved a difference of minus 4.42 versus placebo.
• Effect Sizes: The calculated Cohen's d effect sizes for centanafadine in adults ranged from approximately 0.24 to 0.40 depending on the trial and dose. While these effect sizes are lower than the typical 0.70 to 1.00 associated with stimulants, they are highly comparable to the 0.35 to 0.45 effect sizes observed in registration trials for atomoxetine and viloxazine in adults.

Furthermore, post-hoc analyses presented at the 2026 American Society of Clinical Psychopharmacology (ASCP) annual meeting highlighted the drug's impact beyond core ADHD symptoms. Using the Behavior Rating Inventory of Executive Function (BRIEF) and clinical emotional dysregulation scales, investigators demonstrated that adult patients treated with centanafadine showed statistically significant improvements in executive-functioning domains (such as working memory, planning, and organization) and emotional dysregulation scores compared to placebo, suggesting that triple monoamine reuptake inhibition may provide broad cognitive support.

Pediatric and Adolescent Phase 3 Efficacy Data

To support the pediatric and adolescent indications, Otsuka conducted two separate pivotal trials:

• Adolescent Trial (Ages 13-17): This trial enrolled 459 adolescent patients randomized 1:1:1 to a high dose (328.8 mg), a low dose (164.4 mg), or placebo once daily for six weeks. Efficacy was measured using the ADHD Rating Scale-5 (ADHD-RS-5) investigator-rated version, the standard primary endpoint for pediatric ADHD trials. The high-dose (328.8 mg) arm produced a statistically significant improvement over placebo at week 6, with separation apparent as early as week 1, while the low-dose (164.4 mg) arm did not reach statistical significance on the primary endpoint — a dose-dependent pattern that mirrors the adult program.
• Pediatric Trial (Ages 6-12): A parallel trial enrolled 480 children using weight-based high-dose and low-dose centanafadine arms versus placebo. Efficacy was assessed using the ADHD-RS-5. As in the adolescent study, the high-dose arm met the primary endpoint with statistical superiority over placebo at week 6, while the low-dose arm did not achieve statistical significance. The publication of these pediatric data (Ward et al., Pediatrics Open Science 2025) and adolescent data (Ward et al., JAACAP 2025) provided the peer-reviewed clinical foundation required for regulatory acceptance.

---

How does centanafadine compare with stimulants, atomoxetine, and viloxazine?

For clinical and market-access teams, the positioning of centanafadine depends on how its clinical profile compares to the existing armamentarium of ADHD drugs.

Efficacy and Speed of Onset

Stimulants remain the gold standard for ADHD treatment due to their high efficacy (effect sizes of 0.8 to 1.1) and rapid onset of action, often providing therapeutic benefit within hours of the first dose. Non-stimulants generally require weeks of daily titration to achieve steady-state neurotransmitter modulation and clinical response. Registration data for viloxazine (Qelbree) demonstrated clinical improvement as early as week 2, whereas atomoxetine typically requires 4 to 6 weeks for full therapeutic effect.

Centanafadine's clinical trials demonstrated statistically significant separation from placebo at week 1 or 2, suggesting a potentially faster onset of action than atomoxetine, although head-to-head trials are not available to confirm this comparative speed.

Comparative Molecule Profiles

The absence of dopamine transporter (DAT) affinity in selective NRIs (atomoxetine and viloxazine) completely eliminates the risk of abuse, but it also limits their efficacy in correcting the prefrontal-subcortical dopamine deficit that characterizes ADHD. Centanafadine's triple-reuptake inhibition profile represents an attempt to find a middle ground: introducing a controlled level of DAT blockade to improve dopamine transmission while avoiding the rapid, high-occupancy spikes that lead to euphoria.

---

What is the safety, tolerability, and abuse-potential profile?

The safety profile of centanafadine across its clinical program was generally favorable, with adverse events reflecting its monoaminergic mechanism.

Common Adverse Events

The nature and frequency of adverse events observed in the Phase 3 trials varied slightly by age group:

• Adult Patients: The most common treatment-emergent adverse events (TEAEs) reported in the 200 mg and 400 mg treatment arms were decreased appetite and headache. Other less frequent events included dry mouth, upper respiratory tract infection, and nausea.
• Children and Adolescents: In the pediatric and adolescent Phase 3 trials, the safety profile was characterized by decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence.

Most TEAEs were mild to moderate in severity, occurred early in treatment, and resolved without discontinuation. Discontinuation rates due to adverse events in the active treatment groups were low, typically ranging from 3% to 5%, which is comparable to placebo.

High-Risk Safety Concerns

When evaluating new CNS molecules, safety reviewers pay close attention to high-risk clinical boundaries. In the case of centanafadine:

• Cardiovascular Parameters: Unlike stimulants, which frequently cause clinically significant increases in heart rate and blood pressure, centanafadine was associated with minimal, non-clinically significant changes in average vital signs. There were no signals of corrected QT (QTc) interval prolongation or serious cardiac events in the Phase 3 trials.
• Suicidal Ideation: Selective NRIs like atomoxetine and viloxazine carry FDA boxed warnings regarding the risk of suicidal ideation in children, adolescents, and young adults. In the centanafadine clinical database, there was no signal of treatment-emergent suicidal ideation or behavior, though the FDA will evaluate this closely during the review process and may apply a class-wide warning to non-stimulant agents.
• Abuse Potential: A critical component of centanafadine's NDA is the human abuse potential (HAP) study. Triple reuptake inhibitors have been evaluated for abuse potential because dopamine transporter affinity can theoretically trigger rewarding effects. However, the HAP study for centanafadine demonstrated that at therapeutic doses, the drug did not produce scores on "drug liking" visual analog scales that were significantly different from placebo, and it scored significantly lower than active stimulant comparators (such as methylphenidate). Based on these data, Otsuka has proposed that centanafadine be approved as an unscheduled (non-controlled) medication. The final determination of scheduling rests with the FDA and the DEA, and remains a key regulatory watch point.

---

How should market-access and payer teams prepare if it is approved?

If the FDA approves centanafadine on or before the July 24, 2026 PDUFA date, Otsuka will face the standard launch hurdles associated with new-to-market specialty medications. Payer coverage and formulary placement will be the primary determinants of commercial success.

Payer Barriers in the First 180 Days

In the immediate post-approval period, market-access teams must anticipate the standard defensive mechanisms deployed by commercial insurers and pharmacy benefit managers (PBMs). Most payers implement a "new-to-market block" or a temporary non-formulary designation for the first 180 days following a drug's launch. This block allows PBM clinical committees to review the FDA-approved label, evaluate the clinical evidence, and negotiate manufacturer rebates before establishing permanent coverage criteria. During this window, access is typically restricted to case-by-case medical exceptions or prior authorization overrides. Otsuka will need to support the launch with robust co-pay assistance and patient-access programs to bridge this 180-day gap, a workflow that aligns with established patterns for payer barriers in the first 180 days after launch.

Anticipated Prior-Authorization and Step-Therapy Criteria

Once permanent coverage policies are published, centanafadine is highly likely to be positioned as a non-preferred brand on Tier 3 of commercial formularies, subject to prior authorization (PA) and step-therapy requirements. Payers are incentivized to drive utilization toward low-cost generic alternatives before approving a newly launched branded agent.

The anticipated prior-authorization criteria for centanafadine will likely include:

1. Age and Indication Verification: Diagnosis of ADHD confirmed by DSM-5 criteria, matching the FDA-approved age limits (e.g., ages 6 and older).
2. Specialist Prescriber Requirement: The prescription must be written by, or in consultation with, a psychiatrist, pediatric neurologist, developmental pediatrician, or ADHD specialist.
3. Step-Therapy Hierarchy: Payers will likely require documented failure, intolerance, or contraindication to generic first-line therapies. Because centanafadine is a non-stimulant, payers may structure the step therapy in one of two ways:
   • Stimulant-First Step: Documented failure or contraindication to at least one generic extended-release stimulant (methylphenidate- or amphetamine-based).
   • Non-Stimulant-First Step: Documented failure of generic non-stimulant alternatives, specifically generic atomoxetine or generic alpha-2 agonists (guanfacine ER, clonidine ER).

In many commercial plans, payers require patients to fail both a generic stimulant and a generic non-stimulant (such as atomoxetine) before granting access to a branded non-stimulant like Qelbree. Centanafadine will likely face a similar double-step barrier, meaning clinical teams must document these therapeutic trials in detail.

Step-Therapy Workflow Visualized

Prior-Authorization Decision Path:

• Step 1: Clinical Initiation: The prescriber diagnoses the patient with ADHD and selects centanafadine.
• Step 2: Payer Policy Check:
  • Within 180 Days of Launch: The drug is subject to a New-to-Market Block (requires a manual medical exception override).
  • Post-180 Days: Standard policy rules apply.
• Step 3: Age Restriction Check:
  • Age < 6 years: Coverage denied (outside pediatric indications).
  • Age ≥ 6 years: Proceed to step-therapy trials.
• Step 4: Stimulant Trial Validation:
  • No prior stimulant trial: Payer mandates a trial of a low-cost generic stimulant (e.g., methylphenidate or amphetamine).
  • Prior stimulant failure or contraindication: Proceed to next step.
• Step 5: Non-Stimulant Trial Validation:
  • No prior non-stimulant trial: Payer mandates a trial of generic atomoxetine or guanfacine ER.
  • Prior non-stimulant failure or contraindication: Coverage approved for centanafadine (subject to Tier 3 co-pay).

Commercial Differentiators and Payer Value Prop

To secure favorable formulary placement and minimize step-therapy barriers, Otsuka’s market-access teams must emphasize the value proposition of a non-controlled triple reuptake inhibitor.

The primary access arguments will likely center on:

• The Stimulant Shortage Impact: Highlighting that the ADHD stimulant shortage driving demand for non-stimulant options has left patients with frequent therapy interruptions. A non-controlled, non-stimulant option like centanafadine provides supply stability that Scheduled substances cannot guarantee due to DEA active ingredient quotas.
• Avoidance of Controlled Substance Logistics: Unscheduled status eliminates the administrative burden of monthly paper or electronic Schedule II prescriptions, state-level prescription drug monitoring program (PDMP) checks, and pharmacy refill restrictions, representing a significant workflow benefit for both clinics and patients.
• Favorable Safety Profile: Showcasing the low rate of cardiovascular effects, lack of sleep disruption, and absence of black-box warnings for suicidal ideation (if confirmed by the final label) compared to existing stimulant and non-stimulant options.

---

FAQs

Is centanafadine a stimulant, and could it be used during the amphetamine and methylphenidate shortage?

No, centanafadine is not a stimulant. It is a non-stimulant triple reuptake inhibitor (NDSRI). However, because it inhibits the dopamine transporter in addition to norepinephrine and serotonin transporters, it possesses a novel mechanism that sits between traditional stimulants and selective NRIs.

If approved, it could become a valuable therapeutic option during the ongoing amphetamine and methylphenidate stimulant shortage. Unlike Schedule II stimulants, which face strict manufacturing quotas set by the DEA and require new physical or electronic prescriptions for every fill with no refills allowed, centanafadine is expected to launch as an unscheduled or low-schedule substance. This would allow for standard multi-month prescribing, automatic refills, and a more stable manufacturing supply chain, providing a reliable alternative for patients experiencing treatment interruptions due to stimulant stockouts.

What PDUFA date and review type did the FDA assign the centanafadine NDA?

The FDA accepted the New Drug Application for centanafadine on January 27, 2026, and granted it a priority review. Under the Prescription Drug User Fee Act (PDUFA) guidelines for priority reviews, the FDA set a target action date of July 24, 2026. This six-month review timeline indicates that the FDA views the drug as a potential major improvement in the safety or effectiveness of ADHD treatment. The submission covers pediatric, adolescent, and adult indications simultaneously.

How does centanafadine differ from atomoxetine (Strattera) and viloxazine (Qelbree)?

Centanafadine differs from atomoxetine and viloxazine primarily in its mechanism of action and its clinical trial program:

• Mechanism: Atomoxetine and viloxazine are selective norepinephrine reuptake inhibitors (NRIs) that do not interact significantly with dopamine or serotonin transporters. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). By blocking all three transporters, it increases synaptic levels of all three neurotransmitters, aiming to provide enhanced efficacy by addressing the dopamine and serotonin pathways that selective NRIs miss.
• Abuse Potential: While selective NRIs have zero abuse potential, triple reuptake inhibitors must be rigorously tested for abuse liability due to their dopamine transporter affinity. In clinical human abuse potential studies, centanafadine demonstrated low abuse potential comparable to placebo, whereas stimulants showed high drug liking.
• Trial Scope: Centanafadine's registration program evaluated pediatric, adolescent, and adult populations in parallel, whereas viloxazine was approved in children first and adults later, and atomoxetine had a staggered regulatory timeline.

---

Sources

• Otsuka Pharmaceutical Development & Commercialization, Inc. "Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults." January 27, 2026. Otsuka US Press Releases
• Adler LA, Adams J, Martinez-Varas J, et al. "Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials." Journal of Clinical Psychopharmacology. 2022;42(5):429-439. PubMed
• Ward CL, Childress AC, Greenbaum M, et al. "Efficacy and Safety of Centanafadine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial." Pediatrics Open Science. 2025;3(2):e2024000349. Pediatrics Open Science
• Ward CL, Childress AC, Greenbaum M, et al. "Centanafadine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial." Journal of the American Academy of Child & Adolescent Psychiatry. 2025;64(7):723-734. JAACAP
• Otsuka Pharmaceutical Co., Ltd. "Otsuka Presents New Phase 3 Post-Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 ASCP Annual Meeting." May 28, 2026. Otsuka Global News
• US Centers for Disease Control and Prevention (CDC). "Data and Statistics About ADHD." CDC ADHD Information. Accessed July 1, 2026. CDC Website
• US FDA. "Resources for Information on Approved Drugs: Centanafadine Priority Review Status." FDA CDER Drug Approvals. Accessed July 1, 2026. FDA website